Summary The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in reducing oestrogen levels. The drug's tolerability and clinical efficacy were also assessed. Exemestane was orally administered to four consecutive groups at daily doses of 25, 12.5, 5 and 2.5 mg, and the changes in oestrogen, gonadotrophins, sex-hormone binding globulin and dehydroepiandrosterone sulphate levels were evaluated. Drug selectivity was studied by measuring 17-hydroxycorticosteroid urinary levels. After 7 days of treatment, mean oestrone and oestradiol levels had decreased by respectively 64% and 65% (a decrease which was maintained over time); in the 2.5 mg group, oestrone sulphate levels also decreased by 74%. Gonadotrophin levels were significantly higher, whereas no changes in the other serum hormone levels or any interference with adrenal synthesis were detected. Treatment tolerability was satisfactory: nausea and dyspepsia were reported in 16% of patients. The overall objective response rate was 18%. In conclusion, exemestane is effective in reducing oestrogen levels at all of the tested doses and shows interesting clinical activity.
Aromatase inhibition represents one of the main endocrine treatment options in post-menopausal metastatic breast cancer, and irreversible aromatase inhibitors (steroidal compounds structurally related to the natural substrate androstenedione) have recently been developed.
The first of these to be used in clinical practice was formestane (Coombes et al., 1984; Goss et al., 1986; Hoffken et al., 1990; Pickles et al., 1990; Stein et al., 1990) for which, although it has been described as a 'suicide inhibitor' because of its mechanism of action, possible interference with growth factors has also been evaluated (Reed et al., 1992; . In our experience, it has been found to lead to a significant reduction in oestrogen levels and to have good clinical efficacy (Bajetta et al., 1993 . The preferred route of administration is parenteral because of the drug's rapid and extensive hepatic metabolism; the oral formulation requires higher doses to be effective (Dowsett et al., 1989) . Although local side-effects were mild and infrequent in our experience, other authors have described local pain at the injection site in approximately 14% of patients .
In an attempt to identify an aromatase inhibitor with better oral activity than formestane, a new steroidal derivative, exemestane (FCE 24304) , has been evaluated (Guidici et al., 1988; di Salle et al., 1990) . In animal mammary tumour models, this has been found to be effective in inducing tumour regression when used either orally or by the subcutaneous route (Zaccheo et al., 1989a) , and these results have been confirmed in a model of post-menopausal breast cancer in ovariectomised rats bearing 7,12-dimethylbenzanthracene-induced mammary tumours (Zaccheo et al., 1989b) . A Phase I study using a single oral dose ranging from 0.5 to 800 mg was conducted in 29 healthy post-menopausal volunteers ; the reduction in plasma oestrone (El) , oestradiol (E2) Evans et al., 1992) .
On the basis of these data, we investigated four low exemestane doses administered daily to post-menopausal patients with advanced breast cancer; the present paper reports their endocrine effects, tolerability and clinical efficacy.
Materials and methods

Patient selection
Fifty-six consecutive post-menopausal patients pretreated for advanced breast cancer entered the study, which was conducted at the Medical Oncology Division B of Milan's Istituto Nazionale per lo Studio e le Cura dei Tumori.
Patients were considered eligible only if they had a diagnosis of advanced breast cancer with measurable disease, a performance status of 0-2 (ECOG scale), and positive oestrogen receptor (ER) status as assessed on the primary tumour or metastases. Receptor levels were measured using the dextran-coated charcoal method, and values > 10 and 25 fmol mg-' of cytosol protein were considered positive for ER and progesterone receptors (PgR) respectively; otherwise an immunostaining technique was used. If the receptor status was unknown, a disease-free interval (DFI) of more than 2 years was considered. Post-menopausal status was defined as: 1 year or more since spontaneous menopause; 2 years or more since drug-induced amenorrhea in patients older than 50 years; in the case of patients aged less than 50 years, follicle stimulating hormone (FSH) and luteinising hormone (LH) levels had to be within the post-menopausal range. Patients who had undergone bilateral surgical oophorectomy were also considered. The patients had to have received a previous systemic anti-cancer therapy which had been stopped at least 3 weeks before their entry into the study. The wash-out period was extended up to 6 weeks if drugs in depot formulation had been previously used.
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Patients were excluded if they had endocrine disorders or other concurrent malignant disease or if they were taking concomitant anti-cancer treatments (with the exception of limited radiotherapy fields in the presence of other evaluable lesions). Patients were also considered ineligible if they had significant renal or hepatic dysfunction (creatinine> 1.25 times the upper limit of normal, bilirubin> 1.25 times the upper limit of normal and/or transaminases> 1.25 times the upper limit of normal). Patients with WBC and platelet counts of respectively < 3000 mm-3 and < 100 000 mm-' were excluded, as were those who showed more than onethird liver involvement, lymphangitic lung metastases or brain deposits. Staging and tumour response were defined by means of physical examination, bone scan, chest and skeletal radiographs, liver echography or computed tomographic scan, whole blood cell counts and blood chemistry. These examinations were performed at the beginning of the study, after 56 days as first evaluation, and then every 2 months. Signs, symptoms and toxicity were evaluated according to National Cancer Institute (Bethesda) criteria, and clinical response according to UICC criteria (Hayward et al., 1977) . All of the patients gave their informed consent and the study was approved by the local bioethics committee.
Study design and treatment plan
The study considered four consecutive treatment groups of 14 patients each. Exemestane was supplied by Pharmacia (Farmitalia Carlo Erba) in 2.5, 5, 12.5 and 25 mg capsules, and was taken p.o. at 12 a.m. daily. The first 14 patients entering the study received the highest dose of 25 mg day-1; the next two groups of 14 patients respectively received 12.5 and 5mgday-'; the final 14 patients received 2.5mgday-'.
The patients were seen in an out-patient setting on the day before treatment was started, when they were examined and staged. On the first day of treatment, blood samples were taken at 9 a.m. for endocrine studies and an overnight 12 h urine sample was also collected. The patients were subsequently examined on days 7, 14, 28 and 56, when toxicity was assessed and further blood samples were taken for haematological, biochemical and endocrine studies; urine samples were also collected on days 14, 28 and 56. Tumour response was also evaluated on day 56. Blood was collected at room temperature, allowed to clot, centrifuged at 3000 g and then stored at -20°C until assay. Oestrogen, LH, FSH, sex-hormone binding globulin (SHBG) and dehydroepiandrosterone sulphate (DHEAS) serum levels were all measured when the accrual for each dose group had been completed. In addition, while the study was ongoing and owing to the increasing importance given to EIS in the endocrinological evaluation of women with breast cancer in the recent literature, we decided to test EIS in order to complete the profile of drug activity. Unfortunately, for technical reasons, E,S levels could only be assessed in the last group of patients.
The patients were instructed how to collect overnight 12 h urine and each of them was given a standard plastic tube (volume 1 L, Kartell, Milan, Italy); in order to check that the patients collected all urine volume, they were asked to complete a personal card indicating when and how many times urine had been collected, especially during the night. On examination days, the patients had to return the tube and the card, which was checked by nursing staff. Thereafter, the volume of urine was measured and a 20 ml sample was taken and kept frozen at -20°C until analysis for 17-hydroxycorticosteroids (17-OHCS). If for El and between 70% and 80% for E2. The blank determined in the bidistilled water sample prepared in the same way as the serum sample did not exceed 2 pg per tube for E, and 0.25 pg per tube for E2. The commercially available RIA kits 3H-El (Bio Merieux) and '251-E2 (Clinical Assay) were used to determine El and E2 levels. The standard curve of the E2 kit (supplied in serum) was substituted with a standard curve in buffer. The sensitivity of the assay was 1 pg ml-' for E2 and 4 pg ml-' for El. The intra-assay coefficients of variation (CVs) (n =9) for E2 were 3.1% and 1.8% at 25 pg ml-' and 14 pg ml-' respectively; the intra-assay CVs for El were 8.1% and 9.0% at 39pgml-' and 21 pg ml-' respectively. The interassay CV was 7.7% for El and 6% for E2 (n = 11).
Serum EIS levels were measured by means of RIA after enzyme hydrolysis, liquid phase extraction and chromatographic separation on a Celite column. A serum sample of 3 ml was extracted with 11 ml of diethyl ether to eliminate free steroids, and the ether phase discarded. 3H-EIS (Du Pont Nen Net-203 Estrone Sulphate, ammonium salt [6,7-3H(N)]) was added to the aqueous phase (containing E,S) as a recovery marker, and the solution was submitted to enzyme hydrolysis with 2 mg of sulphatase (Sigma 9626 type H-I) and 3 ml 0.2 M acetate buffer (pH 4.8) and then incubated for 22 h at 45°C. Extraction, chromatographic separation and RIA were carried out as for El. The final recovery was 70-80%. The blank determined in the bidistilled water sample prepared in the same way as the serum sample did not exceed 4pg per tube. The sensitivity of the assay was 8.5 pg ml-'; the intra-assay CV was: 6.1% at 191 pg ml-' (n = 9) and 5.7% at 425 pg ml (n = 7), and the interassay CV was 11%.
Immunoreactive assays were used to determine serum DHEAS, LH, FSH and SHBG levels.
The performance data for these assays were as follows: DHEAS (Sclavo Technogenetics), sensitivity 50 ng ml-', intra-assay CV 6.3% and interassay CV 7.1%; LH (Ares Serono), sensitivity 0.5mUImlm', intra-assay CV 1.1% and interassay CV 2.9%; FSH (Ares Serono), sensitivity 0.5 mUl ml-', intra-assay CV 1.6% and interassay CV 1.7%; SHBG (Orion Corporation), sensitivity 6.25 nmol 1-, intra-assay CV 3.5% and interassay CV 7.1%. All of the samples from individual patients were analysed in the same run of the assay procedure and all of the assays were carried out in duplicate. Urinary adrenal glucocorticoid metabolite levels (jcmol 12 h'-) were determined by means of gas chromatography according to the method of Murphy and West (1966) .
Statistical methods
Except for 17-OHCS, the original values were log-transformed before performing the analyses.
Descriptive statistics (means and 95% confidence intervals) were computed for all hormone levels by dose levels and times of assessment.
Repeated-measurement analyses of variance (ANOVA) were performed to assess the effect of log(dose), time and time x log(dose) interaction factors on hormone levels. The F-tests on within-subject effects were adjusted as described by Huynh and Feldt (1976) . The adopted significance level was 5%.
The best overall response calculated from the time of its onset to the time of progression was considered for the duration of response. Time to treatment failure (TTF) was defined as the period from the date of starting treatment to the date of progression, and analysed using the Kaplan-Meier method.
Results
Patient characteristics
Between January 1992 and February 1993, 56 patients divided into four groups of 14 patients each were sequentially treated with exemestane. All of the patients were assessable in terms of their endocrinological profile and clinical response; their main characteristics are shown in Table I . The four groups were homogeneous in terms of age, ER status and the sites and extent of disease. PgR status was positive in 30, negative in seven and unknown in 19 patients. Approximately 54% of the patients were both ER and PgR positive. The DFI was long in the majority of patients, being less than 2 years in 13; only one patient (in the 12.5 mg group) had no DFI. In 27 patients, spontaneous menopause had lasted for more than 5 years. All of the patients had previously received (Table  III) . Serum DHEAS (Table III) and urinary 17-OHCS (Table  IV) levels remained unchanged during treatment at all of the tested doses. A tendency to increase over time was observed for gonadotrophin levels (Figure 3 ). The trend of E1S serum levels in the 2.5 mg group was in line with those of El and E2
(Table V, Figure 4 ). '95% confidence interval in parentheses.
Table IV Urinary 17-OHCS (jimol 12 h-') during exemestane therapy, expressed as means 17-OHCS 25mg day-' 12.5 mg day-' 5 mg day-' 2.5 mg day-' Day 0 5.1 (4.3-6.0)a 6.8 (4.9-8.6) 5.8 (3.7-7.9) 6.3 (4.8-7.9) 14 5.7 (4.3-7.1) 6.8 (5.4-8.2) 5.7 (3.8-7.7) 5.4 (4.4-6.5) 28 5.2 (4.3-6.0) 5.3 (4.2-6.4) 4.9 (3.5-6.3) 5.7 (4.2-7.3) 56 5.1 (4.0-6.2) 5.9 (4.4-7.5) 5.5 (4.0-6.9) 4.9 (3.8-6.0) '95% confidence interval in parentheses. Between-group comparisons of baseline hormone values showed no difference for any hormone except E2 (P = 0.024), with the E2 baseline values being lower in the 2.5 mg group. At ANOVA, a significant interaction time x log(dose) (P = 0.0476) was found only for E2, the degree of suppression appearing to be less for the lower dose. A significant time factor effect was found for the suppression of El and E2
(P<0.0001). E,S in the 2.5 mg dose group was also Figure 4 Relative changes vs baseline in serum E,S levels during treatment in the 2.5 mg group as a whole.
decreased (P<0.0001), whereas there was a significant increase in LH (P = 0.0375) and FSH (P = 0.0046). Figure  5 . 
Discussion
Exemestane is a novel orally active irreversible aromatase inhibitor and our study shows its effectiveness in suppressing both serum El and E2 levels when given in repeated doses. A significant reduction in serum EIS oestrogen levels was also obtained with the lowest dose of 2.5 mg. The difference in the percentage of E2 reduction obtained with the lowest dose does not seem to be due to any lesser efficacy in inhibiting E2 synthesis, but more probably to the lower E2 baseline values of these patients. Our data also show an effective reduction of EIS levels in the 2.5 mg group, similar to that observed by Evans et al. (1992) using higher single doses.
A statistically significant increase in serum LH and FSH levels was observed during treatment, a finding which has already been reported in other studies using orally administered aromatase inhibitors (Dowsett and Coombes, 1994) . This increase is probably the result of a feedback mechanism due to the reduction in circulating oestrogen levels that stimulates the pituitary secretion of gonadotrophins also in post-menopausal women.
It is known that SHBG reflects the oestrogen-androgen balance as its synthesis is stimulated by oestrogens and inhibited by androgens. In post-menopausal women, SHBG is mainly a marker of androgenic activity. In our study, we found some decrease in SHBG (although this was not statistically significant) and so our data do not support the androgenic activity of the drug. A fall in SHBG has also been shown following high oral doses of formestane (Dowsett and Coombes, 1994) , and has been explained by the rapid increase in drug levels in the liver (the site of SHBG synthesis) following oral absorption. This has not been previously reported for the parenteral administration, of even high doses, probably owing to the short duration of the hormonal study (Goss et al., 1986) ; in a previous experience, we observed a significant decrease in SHBG in patients receiving formestane i.m. but only from the second month of treatment onward . The effects of all of the exemestane doses persisted over time and appeared to be greater than those we have previously described for the other steroidal aromatase inhibitor formestane which, in comparison with baseline, led to an average decrease in E2 serum levels of 40% after 15 days that remained subsequently unchanged, with no difference between the two doses of 250 and 500 mg i.m. every 2 weeks. The efficacy of exemestane in reducing oestrogen levels appears to be lower than that of synthetic derivatives such as letrozole and vorozole, which are capable of reducing oestrogen levels to undetectable levels. In a phase I study with letrozole, Iveson et al. (1993) found that El and E2 plasma levels were suppressed to below the detection limit of the assays regardless of the doses (0.1, 0.5 and 2.5 mg p.o. day-'). The same result was obtained using racemic vorozole at once daily doses of 2.5 or 5 mg (Borms et al., 1991) . In both treatment arms, plasma E2 levels dropped to below the detection limit of the assay within 1 month of treatment. Although the reduction in circulating oestrogen levels is considered to be an expression of the drugs' effectiveness, no clinical relationship has been found (i.e. the higher the oestrogen reduction, the greater the clinical response), and so it is likely that these drugs have more than one mechanism of action. Our data confirm the selectivity of exemestane because no effect on adrenal steroidogenesis was documented by the 17-OHCS urinary excretion measurements.
In our experience, exemestane is a well-tolerated endocrine treatment for advanced breast cancer patients; even the gastrointestinal symptoms which are generally more frequent with oral formulations were reported by only 16% of the patients, and were transient, very mild and not dose related.
In terms of clinical efficacy, our response rate appears to be quite low but, in our opinion, this may be due to the large number of previous treatments. In any case, it was particularly encouraging that two complete responses were obtained, and that three partial responses were obtained with the lowest dose; furthermore, a good number of patients (27%) achieved disease stabilisation lasting at least 6 months.
In conclusion, we think that exemestane may be a useful option in the management of endocrine-dependent advanced breast cancer, and that the good tolerability of the orally administered drug may increase the number of patients suitable for treatment with aromatase inhibitors.
